Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL-111: Parsaclisib in Japanese Subjects With Previously Treated B-Cell Lymphoma
jRCT2080224158Phase 1Completed
- Sponsor
- Incyte
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of parsaclisib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and 2 more, sponsored by Incyte. Primary endpoints: Safety and tolerability of parsaclisib and Pharmacokinetics of parsaclisib. Started Nov 2018; status: completed.
02
Drugs
parsaclisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)mature B-cell lymphoma
Beyond the preview
Go deeper on jRCT2080224158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224158.